Microsoft word - bnfc corrections and clarifications130827.doc


Corrections and clarifications in BNF for Children

There is an error in the benzylpenicillin sodium dose statement for neonates under 7 days, for the treatment of mild-to-moderate susceptible infections (including throat infections, otitis media, pneumonia, cellulitis, neonatal sepsis). The dose should read as follows: Mild to moderate susceptible infections • By intramuscular injection or by
slow intravenous injection or
infusion (intravenous route
recommended in neonates and
infants)

Neonate under 7 days 25 mg/kg every 12 hours; increased to 25 mg/kg every 8 hours if necessary Footnotes 1 and 2 referred to in this section are missing at the bottom of p.733. The two footnotes should be: 1. Live vaccines should be postponed until at systemic corticosteroids and at least 6 months after stopping other immunosuppressive drugs corrected for the print or generalised radiotherapy (at least 12 immunosuppressants following bone-marrow 2. Use of normal immunoglobulin should be considered after exposure to measles (see p.764) and varicella–zoster immunoglobulin considered after exposure to chickenpox or herpes zoster (see p. 768). Children over 2 years with severe acute asthma may be helped by intravenous infusion of magnesium sulphate 40mg/kg (max. 2g) over 20
The route of administration of fentanyl for analgesia and respiratory depression with assisted ventilation in intensive care is unclear. The dose should read as follows: The error will be corrected for the print By intravenous administration
Page 778, column 2 Neonate initially by intravenous injection
intravenous infusion, dose dependent on Child 1 month – 18 years initially by
intravenous infusion, dose dependent on The preparation information for generic The error will be domperidone suspension is incorrect: 5mg/5mL, not 5mg/mL. The entry
Suspension, domperidone 5mg/5mL, net price The route of administration for tramadol for the treatment of Page 259, column 1 administered by intravenous injection and not by mouth.
By intravenous injection (over 2–3 minutes) Page 258, column 1 Child 12–18 years 100 mg initially then 50 mg every 10–20 minutes if necessary up to total max. 250 mg (including initial dose) in first hour, then 50–100 mg every 4–6 hours, max. colitis in children is incorrect. The dose Child 3–18 years initially 0.5–1 mg/kg twice available for other digital versions of BNFC 2007 2006 Book Top of column 1 and ‘Antimalarials’ not ‘Antihistamines’ suspension is incorrect. The preparation Oral suspension, nitrazepam 2.5 mg/5 mL, In the paragraph on Administration (under Phenobarbital), the rate of injection is incorrect and the statement corrected for BNFC For intravenous injection, dilute to a concentration of 20 mg/mL with Water for Injections; give over 20 minutes (no faster than The strength of one of the Tuberculin Purified Protein Derivative preparations is incorrect. The preparation entry Injection, heat-treated products of growth and lysis of appropriate Mycobacterium spp. 20 units/mL (2 units/0.1-mL dose) (for routine The dose shown under the entry for Oxis® Turbohaler® should read as follows: Child 6–18 years 9 micrograms 1–2 times daily; page 164, column 1 occasionally up to 36 micrograms daily may be needed (max. single dose 9 micrograms); reassess treatment if additional doses required on more than 2 days a week Child 6–18 years 4.5–9 micrograms before cefalexin for a child aged 12–18 years. Child 12–18 years 500 mg 2–3 times daily, increased to 1–1.5 g 3–4 times daily for severe

Source: http://www.bnf.org/bnf/popup/BNFC_Corrections.pdf

Cloud_locandina+formiscrizione_22102010

“CLOUD COMPUTING: il percorso obbligato” Martedì 2 novembre 2010 - ore 17 Università degli Studi di Torino - Aula Magna – Rettorato Relatore: Vittorio Viarengo Oggi i clienti dei servizi IT hanno di fronte una realtà piena di sfide. Private cloud e cloud computing promettono un sistema di fornitura di servizi IT più agile e orientato al cliente. Vittorio ci porterà in u

dal.ca

Standards of Practice for Canadian Pharmacists A p r i l 2 0 0 3 National Association of Pharmacy Regulator y Authorities (NAPRA) Publication supported by © National Association of Pharmacy Regulatory Authorities, 2003. All rightsreserved. No part of this document may be reproduced in any form by anyphotographic, electronic, mechanical or other means, or used in any inform

Copyright 2014 Pdf Medic Finder